alendronate and pamidronate

alendronate has been researched along with pamidronate in 168 studies

Research

Studies (168)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	28 (16.67)	18.2507
2000's	82 (48.81)	29.6817
2010's	50 (29.76)	24.3611
2020's	8 (4.76)	2.80

Authors

Authors	Studies
Alferiev, IS; Amidon, GL; Breuer, E; Cohen, H; El Hanany-Rozen, N; Ezra, A; Gati, I; Golomb, G; Hoffman, A; Mönkkönen, J; Stepensky, D; Törmälehto, S; Weiss, G	1
Bailey, BN; Docampo, R; Rodriguez, JB; Szajnman, SH	1
Bailey, BN; Caldera, A; Croft, SL; Docampo, R; Grimley, JS; Heath, HT; Kendrick, H; Lewis, JC; Lira, R; Martin, MB; Moreno, SN; Oldfield, E; Urbina, JA; Yardley, V	1
Cieslak, JA; Coates, RM; Fukura, S; Koohang, A; Lea, CR; Lee, HJ; Loftus, TC; Martin, MB; Matsumura, Y; Oldfield, E; Sagami, H; Sanders, JM; Sengupta, S; Szabo, CM	1
Martin, MB; Oldfield, E; Szabo, CM	1
Bachmann, R; Bisping, M; Born, AR; Cortesi, R; Glatt, M; Green, JR; Guiglia, G; Jaeggi, KA; Jeker, H; Klein, R; Müller, K; Ramseier, U; Schmid, J; Schreiber, G; Seltenmeyer, Y; Widler, L	1
Gossman, W; Oldfield, E	1
Burzynska, A; Gómez, AO; González-Pacanowska, D; Kafarski, P; Mao, J; Meints, GA; Oldfield, E; Sanders, JM; Van Brussel, EM	1
Bruchhaus, I; Chan, JM; Croft, SL; Flessner, RM; Ghosh, S; Kemp, RG; Kendrick, H; Kobayashi, S; Lea, CR; Lewis, JC; Loftus, TC; Meints, GA; Nozaki, T; Oldfield, E; Tovian, ZS	1
Burzynska, A; Chan, JM; Colantino, A; Ghosh, S; Kafarski, P; Meints, G; Morita, CT; Oldfield, E; Raker, AM; Sanders, JM; Song, Y; Wang, H	1
Craig, SP; Delfino, JM; Fernández, D; Wenck, MA	1
Chan, JM; Flessner, R; Gómez, AO; González-Pacanowska, D; Jennings, S; Kosztowski, T; Kotsikorou, E; Meints, GA; Morita, CT; Odeh, S; Oldfield, E; Papapoulos, SE; Raker, AM; Sanders, JM; Schwerdtfeger, C; Song, Y; van Beek, ER; Wang, H; Zhang, Y	1
Araujo, FG; Chan, JM; Ling, Y; Moreno, SN; Odeh, S; Oldfield, E; Sahota, G	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Barnett, BL; Dunford, JE; Ebetino, FH; Kavanagh, KL; Kwaasi, AA; Oppermann, U; Rogers, MJ; Russell, RG	1
Axelson, J; Cao, R; Chang, SC; Chang, TH; Guo, RT; Hudock, MP; K-M Chen, C; Ko, TP; Kumar, A; Liang, PH; No, JH; Oldfield, E; Song, Y; Wang, AH; Zhang, Y	1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ	1
Berlicki, Ł; Kafarski, P; Mucha, A	1
Lecouvey, M; Monteil, M; Puljula, E; Turhanen, P; Vepsäläinen, J; Weisell, J	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Artyushin, OI; Brel, VK; Chuprov-Netochin, RN; Leonov, SV; Semenov, VV; Semenova, MN	1
Almeida Paz, FA; Barbosa, JS; Braga, SS	1
Bauss, F; Bosies, E; Fleisch, H; Janner, M; Mühlbauer, RC; Schenk, R; Strein, K	1
Koiso, K; Miyagawa, I; Nemoto, R; Satou, S	1
Grasser, W; Sato, M	1
Harada, M; Koiso, K; Miyakawa, I; Nemoto, R; Nishijima, Y; Sato, S	1
Warrell, RP	1
Azuma, Y; Kiyoki, M; Ohta, T; Okabe, K; Oue, Y; Sato, H; Tsuchimoto, M	1
Ammann, P; Bonjour, JP; Budayr, AA; Burckhardt, P; Gertz, B; Jaquet-Müller, F; Jenzer, A; Rizzoli, R; Thiébaud, D; Zysset, E	1
Collin, P; Fleisch, H; Guenther, HL; Martin, TJ; Sahni, M	1
Hirvonen, MR; Makkonen, N; Mönkkönen, J; Savolainen, K; Teräväinen, T	1
Chilton, KM; Coxon, FP; Lawry, J; Rogers, MJ; Russell, RG; Smith, MO; Suri, S	1
Licata, AA	1
Body, JJ; Coleman, RE; Piccart, M	1
Adachi, H; Hirafuji, M; Igarashi, K; Mitani, H; Shinoda, H	1
Berman, SK; Blank, MA; Ems, BL; Gibson, GW; Myers, WR; Phipps, RJ; Smith, PN	1
Fleisch, HA	1
Bonde, M; Christiansen, C; Delmas, PD; Fledelius, C; Garnero, P; Qvist, P	1
Hara, N; Nakanishi, Y; Takayama, K	1
Greenwald, RA; Miller, F; Stein, B	1
Alferiev, IS; Breuer, E; Cohen, H; Eidelman, N; Golomb, G; Hägele, G; Ornoy, A; Patlas, N; Solomon, V	1
Azuma, Y; Kanatani, H; Kiyoki, M; Komoriya, K; Ohta, T; Oue, Y	1
Brosch, S; Peterlik, M; Pietschmann, P; Smolen, JS; Steiner, G; Stohlawetz, P	1
Knowles, S; Phillips, E; Shear, NH; Weber, E	1
Den Hartigh, J; Pas, O; Ramp-Koopmanschap, W; Twiss, IM; Vermeij, P	1
Hanemaaijer, R; Heikkilä, P; Konttinen, YT; Laitinen, M; Maisi, P; Salo, T; Sorsa, T; Teronen, A; Teronen, O	1
Alferiev, IS; Breuer, E; Cohen, H; Ezra, A; Golomb, G; Hägele, G; Hoffman, A; Mönkkönen, J; Ornoy, A; Patlas, N; Pinto, T; Sagi, H; Seibel, MJ; Solomon, V; Stepensky, D	1
Bhagat, CI; Criddle, A; Faulkner, DL; Gan, SK; Geelhoed, E; Gutteridge, DH; Kent, GN; Price, RI; Prince, RL; Retallack, RW; Stewart, GO; Stuckey, BG; Vasikaran, S; Ward, LC; Will, RK	1
Bellido, T; Manolagas, SC; Parfitt, AM; Plotkin, LI; Roberson, PK; Weinstein, RS	1
Bastaki, S; Blank, MA; Dicay, M; McKnight, W; Wallace, JL	1
Berenson, J; Hortobagyi, G; Lipton, A; Major, PP	1
Bergstrom, JD; Bostedor, RG; Masarachia, PJ; Reszka, AA; Rodan, G	1
Daley, J; Hartman, EE	1
Adami, S; Braga, V; Fracassi, E; Gatti, D; Gerardi, D; Guidi, G	1
Bauer, E; Feurle, J; Kunzmann, V; Tony, HP; Weissinger, F; Wilhelm, M	1
Blank, MA; Dierckman, TA; Gibson, GW; Myers, WR; Phipps, RJ; Smith, PN	1
Ball, DW; Basaria, S; Belzberg, AJ; McCarthy, EF	1
Blank, MA; Gibson, GW; Lichtenberger, LM; Romero, JJ	1
Papapoulos, SE	1
Brand, J; Curtin, J; Hommen, JP; Khan, SN; Lane, JM; Nydick, M; O'Connor, WJ; Schneider, R; Tomin, E	1
Watts, NB	1
Bukowski, JF; Das, H; Kamath, A; Wang, L	1
Gutteridge, DH; Kent, GN; Lim, EM; Stuckey, BG; Ward, LC	1
Cahill, BC; Karwande, SV; Knecht, TP; O'Rourke, MK; Parker, S; Stringham, JC	1
Gomez-Acotto, C; Mautalen, C; Zeni, S	1
Chandia, M; Costa, MC; Costa, MR; Fausto, R; Gano, L; Neves, M; Pereira, N; Rosado, M	1
Jeong-Hwa, B; Kim, GS; Kim, YH	1
Heijckmann, AC; Juttmann, JR; Wolffenbuttel, BH	1
Bergmann, P; Body, JJ; Dumon, JC; Fellemans, C; Fuss, M; Peretz, A; Rozenberg, S; Siderova, V	1
Kotsikorou, E; Oldfield, E	1
Epstein, M; Joshua, F; Major, G	1
Cheng, YY; Huang, L; Kumta, SM; Lee, KM; Xu, JK; Zheng, MH	1
Bhagat, CI; Criddle, RA; Dhaliwal, SS; Drury, PJ; Gutteridge, DH; Kent, GN; Prince, RL; Retallack, RW; Stewart, GO; Stuckey, BG; Vasikaran, S; Walsh, JP; Ward, LC; Will, RK	1
Gharib, S	1
Boos, J; Lanvers-Kaminsky, C; Vorotnjak, M	1
Dimeglio, LA; Ford, L; McClintock, C; Peacock, M	1
Abrahamsen, B; Brixen, KT; Kassem, MS; Mosekilde, L	1
Carter, G; Doecke, C; Goss, AN	1
Bultink, IE; Dijkmans, BA; Lems, WF; Vis, M	1
Cortizo, AM; McCarthy, AD; Vaisman, DN	1
Azzarello, G; Balducci, E; Crepaldi, G; Dalle Carbonare, L; Giannini, S; Realdi, G; Valenti, MT; Vinante, O	1
Hande, K; Richardson, PG; Woo, SB	1
Kwon, KI; Yun, MH	1
Bourgeois, SL; Goodell, GG; Sarathy, AP	1
Broumand, V; Fortin, M; Marx, RE; Sawatari, Y	1
DiMeglio, LA; Peacock, M	1
Eufinger, H; Hoefert, S	1
Robb-Nicholson, C	1
Bosch, JJ; Burggraaf, J; Cohen, AF; de Kam, ML; Twiss, IM; van den Berk, AH; Vermeij, P	1
Alexander, RE	1
Franke, HR; Verdijk, R; Vermes, I; Wolbers, F	1
Anderson, EI; Bexheti, D; Hanna-Brown, M; Hutt, AJ	1
Langdahl, B; Mosekilde, L; Vestergaard, P	1
Alati, C; Allegra, A; Alonci, A; Cicciù, M; De Ponte, FS; Musolino, C; Nastro, E; Oteri, G; Quartarone, E	1
Bonaninil, M; Corcione, L; Corradi, D; D'Aleo, P; Ferrari, S; Guidotti, R; Manfredi, M; Meleti, M; Merigo, E; Poli, T; Ripasarti, A; Sesenna, E; Vescovi, P; Zanzucchi, E	1
Azzarello, G; Balducci, E; Bertoldo, F; Dalle Carbonare, L; Fracalossi, A; Lo Cascio, V; Valenti, MT; Vinante, O	1
Ji, T; Ruan, M; Zhang, CP	1
Dulea, C; Gherase, A; Savu, SR; Silvestro, L; Tarcomnicu, I	1
Mukherjee, S; Oldfield, E; Song, Y	1
Damiani, D	1
Bianchi, ML; Biggioggero, M; Frasunkiewicz, J; Limonta, C; Vai, S	1
Greig, IR; Idris, AI; Ralston, SH; Rojas, J; Van't Hof, RJ	1
Chagin, AS; Heino, TJ; Sävendahl, L; Takigawa, M	1
French, DD; Margo, CE	1
Goepferich, A; Mayr, H; Schuessele, A; Tessmar, J	1
Silverman, SL	1
Arnol, V; Cortizo, AM; Felice, JI; Gangoiti, MV; McCarthy, AD	1
Bigi, A; Bracci, B; Fini, M; Panzavolta, S; Torricelli, P	1
Yamashita, S	2
Choi, D; Fraunfelder, FT; Fraunfelder, FW; Suhler, E; Winthrop, K	1
Geusens, P	1
Elad, S; Hardan, I; Lazarovici, TS; Taicher, S; Yahalom, R; Yarom, N	1
Christou, S; Efstathiou, E; Ioannou, YS; Kyriakou, A; Savva, SC; Savvides, I; Skordis, N	1
Balasanian, E; Stanton, DC	1
Baer, D; Han, MM; Hui, RL; Khoury, S; Liao, W; Liberty, D; Lo, JC; Martin, D; O'Ryan, FS	1
Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A	1
Lamprecht, G	1
Carter, T; Cole, C; Kotecha, RS; Lee, SJ; Murray, KJ; Powers, N	1
Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M	1
Henry, C; Jahnke, W	1
Friedland, B; Treister, NS; Woo, SB	1
Friedrich, NF; Graf, C; Kraenzlin, C; Kraenzlin, ME; Meier, C	1
Arduino, PG; Broccoletti, R; Dalmasso, P; Mozzati, M; Scoletta, M	1
Gillen, C; Nunes, M; Shapiro, JR; Thompson, CB; Wu, Y	1
Byard, S; Duer, MJ; Ironside, MS; Reid, DG	1
Darmon, P; Molines, L; Raccah, D	1
Dabbous, MKh; Seshul, BA; Tipton, DA	1
Kwon, SR; Lim, MJ; Park, SG; Park, W	1
Hussein, O; Komarova, SV; Tiedemann, K	1
Barrs, VR; Beatty, JA; Briscoe, KA; Whitney, JL; Wilkinson, MR	1
Correia, JD; Gano, L; Oliveira, BL; Palma, E; Santos, I; Santos, IC	1
Alloh Amichia, YC; Giumelli, B; Le Bars, P; Soueidan, A	1
Goltz, D; Jauch, C; Schott, H; Schott, TC; Schwendener, RA	1
Kwon, YD; Lee, HW; Ohe, JY	1
Bartl, R	1
Marchetti, C; Montebugnoli, L; Moretti, F; Pelliccioni, GA	1
Alasti, M; Beladi Mousavi, SS; Ghorbani, A; Omidvar, B; Shahbazian, H; Shariat Nabavi, SJ	1
Açil, Y; Gassling, V; Möller, B; Niehoff, P; Rachko, K; Simon, MJ; Wiltfang, J	1
Boulman, N; Kaly, L; Rimar, D; Rosner, I; Rozenbaum, M; Slobodin, G	1
Carson, DA; Cho, JS; Corr, M; Crain, B; Hayashi, T; Miller, LS; Norton, JT	1
Grätz, KW; Jacobsen, C; Metzler, P; Obwegeser, J; Rössle, M; Zemann, W	1
Freiberger, JJ; Kraft, KH; McGraw, T; Moon, RE; Padilla-Burgos, R; Piantadosi, CA; Stolp, BW; Suliman, HB	1
Chen, M; Chen, Y; Chen, Z; Liu, Y; Zhu, Y	1
Abbas, FM; Behnia, H; Dashti, SG; Dehghan, MM; Khojasteh, A; Morad, G; Shahab, S	1
Afsie, S; Al-Nammari, SS; Timothy, T	1
Bouxsein, ML; Brooks, DJ; Demay, MB; Louis, L; Zhu, ED	1
Chikazu, D; Hamada, H; Koizumi, T; Matsuo, A; Satomi, T	1
Bohgaki, M; Goto, M; Imoto, S; Matsumoto, E; Saigo, K	1
De Luna-Bertos, E; García-Martínez, O; Manzano-Moreno, FJ; Ramos-Torrecillas, J; Ruiz, C	1
Araz, K; Dagdeviren, A; Helvacioglu, F; Sahin, F; Senel, FV; Soydan, SS; Tekindal, MA; Yurtcu, E	1
Beecham, E; Bluebond-Langner, M; Candy, B; Howard, R; Jones, L; Laddie, J; McCulloch, R; Rees, H; Vickerstaff, V	1
Bhethanabotla, VR; Conners, CM; Gupta, VK	1
Cunneen, TS; Goold, LA; Leibovitch, I; Martin, P; Pirbhai, A; Rajak, SN; Selva, D; Wilcsek, G	1
Amin, NL; James, RM; Phillips, R	1
Mészaros, Á; Veszelyné Kotán, E	2
González, R; López-Posadas, R; Martínez-Augustin, O; Mascaraque, C; Sánchez de Medina, F; Suárez, MD; Zarzuelo, A	1
Casasnovas, R; Fernández, D; Frau, J; Ortega-Castro, J; Ramis, R; Vilanova, B	1
Filella, X; Florez, H; Guañabens, N; Mandelikova, S; Monegal, A; Peris, P	1
Dehghan, MM; Khojasteh, A; Nazeman, P	1
Chowdhury, A; Karamched, SR; Nosoudi, N; Parasaram, V; Parrish, J; Siclari, S	1
Hanioka, Y; Harada, D; Izui, M; Kashiwagi, H; Kishimoto, K; Kondo, K; Nagamatsu, Y; Namba, N; Oriyama, K; Sakamoto, N; Seino, Y; Tanaka, H; Ueyama, K; Yamada, H	1
Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM	1
Chworos, A; Gostynski, B; Madaj, R; Pawlowska, R	1
Chang, AB; Conwell, LS; Jeffery, TC	1
Bhardwaj, A; Sinha, NK; Swe, KMM	1
Chen, Y; Huang, Y; Xiao, Y	1

Reviews

26 review(s) available for alendronate and pamidronate

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Bisphosphonates, Old Friends of Bones and New Trends in Clinics. Journal of medicinal chemistry, 2021, 02-11, Volume: 64, Issue:3 Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug Compounding; Drug Delivery Systems; Humans	2021
Hypercalcemia and bone metastases in breast cancer. Current opinion in oncology, 1990, Volume: 2, Issue:6 Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hypercalcemia; Neoplasm Proteins; Pamidronate; Parathyroid Hormone-Related Protein; Proteins; Transforming Growth Factors	1990
Bisphosphonate therapy. The American journal of the medical sciences, 1997, Volume: 313, Issue:1 Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoclasts; Osteoporosis; Osteoporosis, Postmenopausal; Pamidronate; Risedronic Acid	1997
Use of bisphosphonates in cancer patients. Cancer treatment reviews, 1996, Volume: 22, Issue:4 Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Multiple Myeloma; Osteolysis; Pain; Pamidronate; Structure-Activity Relationship	1996
Bisphosphonates: preclinical aspects and use in osteoporosis. Annals of medicine, 1997, Volume: 29, Issue:1 Topics: Alendronate; Animals; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Osteoporosis; Pamidronate	1997
[Paraneoplastic syndrome]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24 Suppl 3 Topics: Alendronate; Anticoagulants; Cushing Syndrome; Diagnosis, Differential; Diphosphonates; Disseminated Intravascular Coagulation; Diuretics; Furosemide; Heparin; Humans; Hypercalcemia; Inappropriate ADH Syndrome; Lung Neoplasms; Pamidronate; Paraneoplastic Syndromes	1997
Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer, 2000, Jan-01, Volume: 88, Issue:1 Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid	2000
Bisphosphonates in the treatment of osteoporosis. Principles and efficacy. Annales de medecine interne, 2000, Volume: 151, Issue:6 Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Bone Density; Calcium Channel Blockers; Controlled Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Pamidronate; Papio; Prospective Studies; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Time Factors	2000
Treatment of osteoporosis with bisphosphonates. Rheumatic diseases clinics of North America, 2001, Volume: 27, Issue:1 Topics: Aged; Alendronate; Bone and Bones; Bone Density; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Risedronic Acid	2001
[Pharmacological treatment of osteitis deformans (Paget's bone disease)]. Ugeskrift for laeger, 2005, Feb-28, Volume: 167, Issue:9 Topics: Alendronate; Analgesics, Non-Narcotic; Antimetabolites; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Osteitis Deformans; Pamidronate; Radionuclide Imaging; Risedronic Acid	2005
Fracture prevention in postmenopausal women. Clinical evidence, 2006, Issue:15 Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Hormone Replacement Therapy; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Pamidronate; Parathyroid Hormone; Risedronic Acid; Selective Estrogen Receptor Modulators; Vitamin D	2006
Paget disease of bone: therapeutic options. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2008, Volume: 14, Issue:5 Topics: Alendronate; Alkaline Phosphatase; Anti-Inflammatory Agents; Diphosphonates; Etidronic Acid; Humans; Osteitis Deformans; Pamidronate; Retreatment; Risedronic Acid; Treatment Outcome	2008
[Bisphosphonates and other new therapeutic agents for the treatmednt of osteogenesis imperfecta]. Clinical calcium, 2009, Volume: 19, Issue:2 Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Child, Preschool; Clinical Trials as Topic; Denosumab; Diphosphonates; Drug Administration Schedule; Genetic Therapy; Humans; Imidazoles; Infusions, Intravenous; Osteogenesis Imperfecta; Pamidronate; RANK Ligand; Severity of Illness Index; Stem Cell Transplantation; Teriparatide; Zoledronic Acid	2009
Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Current osteoporosis reports, 2009, Volume: 7, Issue:1 Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fracture Healing; Fractures, Bone; Humans; Jaw Diseases; Middle Aged; Osteonecrosis; Osteoporosis, Postmenopausal; Pamidronate; Risedronic Acid	2009
[Bone and joint diseases in children. Bisphosphonates in osteogenesis imperfecta]. Clinical calcium, 2010, Volume: 20, Issue:6 Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Humans; Imidazoles; Infant; Infusions, Intravenous; Osteogenesis Imperfecta; Pamidronate; Severity of Illness Index; Zoledronic Acid	2010
Charcot's foot: newest findings on its pathophysiology, diagnosis and treatment. Diabetes & metabolism, 2010, Volume: 36, Issue:4 Topics: Alendronate; Arthropathy, Neurogenic; Biomarkers; Bone Density Conservation Agents; Calcitonin; Diabetic Foot; Diagnosis, Differential; Diphosphonates; Early Diagnosis; Foot Deformities, Acquired; Foot Injuries; Humans; Osteoprotegerin; Pamidronate; Randomized Controlled Trials as Topic; RANK Ligand; Weight-Bearing	2010
A Surgeon's guide to advances in the pharmacological management of acute Charcot neuroarthropathy. Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons, 2013, Volume: 19, Issue:4 Topics: Alendronate; Alkaline Phosphatase; Arthropathy, Neurogenic; Bone Density Conservation Agents; Calcitonin; Diphosphonates; Humans; Hydroxyproline; Imidazoles; Immobilization; Insulin-Like Growth Factor I; Pamidronate; Randomized Controlled Trials as Topic; RANK Ligand; Skin Temperature; Zoledronic Acid	2013
Pharmacological interventions for pain in children and adolescents with life-limiting conditions. The Cochrane database of systematic reviews, 2015, Mar-13, Issue:3 Topics: Adolescent; Alendronate; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Child; Child, Preschool; Diphosphonates; Gastrointestinal Diseases; Humans; Injections, Spinal; Neuromuscular Agents; Osteogenesis Imperfecta; Pain; Pamidronate; Seizures; Young Adult	2015
Bisphosphonate-Induced Orbital Inflammation: A Case Series and Review. Orbit (Amsterdam, Netherlands), 2015, Volume: 34, Issue:6 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Orbital Cellulitis; Orbital Myositis; Pamidronate; Radiography; Retrospective Studies; Zoledronic Acid	2015
QUESTION 1: Should we be using bisphosphonates for osteonecrosis complicating childhood acute lymphoblastic leukaemia? Archives of disease in childhood, 2016, Volume: 101, Issue:3 Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteonecrosis; Pain; Pamidronate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risedronic Acid	2016
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I]. Acta pharmaceutica Hungarica, 2016, Volume: 86, Issue:1 Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid	2016
Bisphosphosphonate-calcium phosphate cement composite and its properties. Bio-medical materials and engineering, 2019, Volume: 30, Issue:3 Topics: Alendronate; Animals; Biocompatible Materials; Bone Density Conservation Agents; Calcium Phosphates; Diphosphonates; Drug Carriers; Drug Delivery Systems; Etidronic Acid; Humans; Pamidronate; Zoledronic Acid	2019
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Denosumab; Diphosphonates; Etidronic Acid; Humans; Male; Network Meta-Analysis; Pamidronate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Zoledronic Acid	2020
Bisphosphonates for osteoporosis in people with cystic fibrosis. The Cochrane database of systematic reviews, 2023, 01-10, Volume: 1 Topics: Adult; Alendronate; Bone Density Conservation Agents; Child; Cystic Fibrosis; Diphosphonates; Female; Fractures, Bone; Humans; Musculoskeletal Pain; Osteoporosis; Pamidronate; Quality of Life; Randomized Controlled Trials as Topic; Spinal Fractures; Zoledronic Acid	2023
Treatment for osteoporosis in people with beta-thalassaemia. The Cochrane database of systematic reviews, 2023, 05-09, Volume: 5 Topics: Adult; Alendronate; beta-Thalassemia; Child; Clodronic Acid; Denosumab; Diphosphonates; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Pamidronate	2023

Trials

17 trial(s) available for alendronate and pamidronate

Article	Year
Hypercalcemia and bone metastases in breast cancer. Current opinion in oncology, 1990, Volume: 2, Issue:6 Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hypercalcemia; Neoplasm Proteins; Pamidronate; Parathyroid Hormone-Related Protein; Proteins; Transforming Growth Factors	1990
Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1999, Volume: 14 Suppl 2 Topics: Aged; Alendronate; Diphosphonates; Drug Resistance; Female; Humans; Male; Osteitis Deformans; Pamidronate	1999
Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2000, Volume: 15, Issue:3 Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diphosphonates; Female; Humans; Infusions, Intravenous; Isoenzymes; Osteoporosis, Postmenopausal; Pamidronate; Structure-Activity Relationship; Triglycerides	2000
Prevention of bone loss and fracture after lung transplantation: a pilot study. Transplantation, 2001, Oct-15, Volume: 72, Issue:7 Topics: Absorptiometry, Photon; Adult; Alendronate; Bone Density; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Lumbar Vertebrae; Lung Transplantation; Male; Middle Aged; Osteoporosis; Pamidronate; Preoperative Care; Prospective Studies; Treatment Outcome	2001
Response to alendronate in osteoporotic women previously treated with pamidronate. Maturitas, 2003, Feb-25, Volume: 44, Issue:2 Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Bone Density; Calcium; Collagen; Dietary Supplements; Diphosphonates; Female; Hip; Humans; Injections, Intravenous; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Pamidronate; Prospective Studies; Treatment Outcome; Vitamin D	2003
Bisphosphonate resistance in Paget's disease of bone. Arthritis and rheumatism, 2003, Volume: 48, Issue:8 Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Anti-Inflammatory Agents; Clodronic Acid; Diphosphonates; Drug Resistance; Humans; Injections, Intravenous; Middle Aged; Osteitis Deformans; Pamidronate	2003
A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Bone, 2004, Volume: 34, Issue:4 Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Calcium; Diphosphonates; Female; Humans; Injections, Intravenous; Male; Osteitis Deformans; Pain; Pamidronate; Quality of Life	2004
A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of pediatric endocrinology & metabolism : JPEM, 2005, Volume: 18, Issue:1 Topics: Administration, Oral; Adolescent; Age Factors; Alendronate; Anti-Inflammatory Agents; Bone Density; Child; Child Development; Child, Preschool; Diphosphonates; Female; Humans; Infusions, Intravenous; Male; Osteogenesis Imperfecta; Pamidronate; Prospective Studies; Severity of Illness Index; Treatment Outcome	2005
Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2006, Volume: 21, Issue:1 Topics: Administration, Oral; Alendronate; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Child; Diphosphonates; Female; Fractures, Bone; Humans; Incidence; Injections, Intravenous; Male; Osteogenesis Imperfecta; Pamidronate; Prospective Studies	2006
A comparison of the gastrointestinal effects of the nitrogen-containing bisphosphonates pamidronate, alendronate, and olpadronate in humans. Journal of clinical pharmacology, 2006, Volume: 46, Issue:4 Topics: Adult; Alendronate; Bone Density Conservation Agents; Cross-Over Studies; Diphosphonates; Female; Gastrointestinal Diseases; Humans; Pamidronate; Single-Blind Method	2006
Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major. Pediatric endocrinology reviews : PER, 2008, Volume: 6 Suppl 1 Topics: Absorptiometry, Photon; Adult; Alendronate; beta-Thalassemia; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Male; Middle Aged; Osteoporosis; Pamidronate; Retrospective Studies; Young Adult	2008
Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL). Pediatric blood & cancer, 2010, Jul-01, Volume: 54, Issue:7 Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Alendronate; Antineoplastic Combined Chemotherapy Protocols; Calcium; Child; Child, Preschool; Combined Modality Therapy; Diphosphonates; Female; Humans; Incidence; Infusions, Intravenous; Male; Osteonecrosis; Pain; Pamidronate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy; Risk Factors; Vitamin D	2010
Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta. Calcified tissue international, 2010, Volume: 87, Issue:2 Topics: Administration, Oral; Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Cohort Studies; Diphosphonates; Female; Fractures, Bone; Humans; Injections, Intravenous; Male; Osteogenesis Imperfecta; Pamidronate; Retrospective Studies; Treatment Outcome	2010
A prospective clinical trial for assessing the efficacy of a minimally invasive protocol in patients with bisphosphonate-associated osteonecrosis of the jaws. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2011, Volume: 112, Issue:6 Topics: Aged; Aged, 80 and over; Alendronate; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Local; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Chlorhexidine; Diphosphonates; Drug Combinations; Female; Follow-Up Studies; Humans; Imidazoles; Male; Metronidazole; Middle Aged; Mouthwashes; Oral Hygiene; Pain Measurement; Pamidronate; Prospective Studies; Salicylates; Terpenes; Treatment Outcome; Zoledronic Acid	2011
Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation. Iranian journal of kidney diseases, 2011, Volume: 5, Issue:6 Topics: Absorptiometry, Photon; Administration, Oral; Adult; Alendronate; Anti-Inflammatory Agents; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Injections, Intravenous; Kidney Diseases; Kidney Transplantation; Male; Middle Aged; Pamidronate; Time Factors; Treatment Outcome; Young Adult	2011
What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2012, Volume: 70, Issue:7 Topics: Aged; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Combined Modality Therapy; Debridement; Diphosphonates; Female; Follow-Up Studies; Gingiva; Humans; Hyperbaric Oxygenation; Imidazoles; Male; Multiple Myeloma; Osteoporosis; Pain Management; Pamidronate; Prospective Studies; Quality of Life; Treatment Outcome; Wound Healing; Zoledronic Acid	2012
Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatment. Journal of pediatric endocrinology & metabolism : JPEM, 2020, Nov-26, Volume: 33, Issue:11 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Humans; Infant; Infant, Newborn; Infusions, Intravenous; Japan; Maintenance Chemotherapy; Male; Osteogenesis Imperfecta; Pamidronate; Treatment Outcome	2020

Other Studies

126 other study(ies) available for alendronate and pamidronate

Article	Year
A peptide prodrug approach for improving bisphosphonate oral absorption. Journal of medicinal chemistry, 2000, Oct-05, Volume: 43, Issue:20 Topics: Administration, Oral; Alendronate; Animals; Biological Availability; Caco-2 Cells; Carrier Proteins; Chemical Precipitation; Dipeptides; Diphosphonates; Durapatite; Humans; Injections, Intravenous; Intestinal Absorption; Pamidronate; Peptide Transporter 1; Prodrugs; Rats; Symporters; Tissue Distribution	2000
Bisphosphonates derived from fatty acids are potent growth inhibitors of Trypanosoma cruzi. Bioorganic & medicinal chemistry letters, 2001, Mar-26, Volume: 11, Issue:6 Topics: Animals; Bone Resorption; Diphosphonates; Fatty Acids; Humans; Inhibitory Concentration 50; Parasitic Sensitivity Tests; Trypanocidal Agents; Trypanosoma cruzi; United States; United States Food and Drug Administration	2001
Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. Journal of medicinal chemistry, 2001, Mar-15, Volume: 44, Issue:6 Topics: Animals; Antiprotozoal Agents; Chlorocebus aethiops; Diphosphonates; Leishmania donovani; Plasmodium falciparum; Structure-Activity Relationship; Toxoplasma; Trypanosoma brucei brucei; Trypanosoma cruzi; Vero Cells	2001
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. Journal of medicinal chemistry, 2002, May-23, Volume: 45, Issue:11 Topics: Alkyl and Aryl Transferases; Antiparasitic Agents; Bone Resorption; Diphosphonates; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Models, Molecular; Organophosphates; Quantitative Structure-Activity Relationship; Recombinant Proteins	2002
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs. Journal of medicinal chemistry, 2002, Jul-04, Volume: 45, Issue:14 Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Quantitative Structure-Activity Relationship; Rats	2002
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). Journal of medicinal chemistry, 2002, Aug-15, Volume: 45, Issue:17 Topics: Animals; Bone Resorption; Calcitriol; Diphosphonates; Hypercalcemia; Imidazoles; In Vitro Techniques; Kidney; Mice; Pamidronate; Parathyroidectomy; Rats; Skull; Structure-Activity Relationship; Thyroidectomy; Zoledronic Acid	2002
Quantitative structure--activity relations for gammadelta T cell activation by phosphoantigens. Journal of medicinal chemistry, 2002, Oct-24, Volume: 45, Issue:22 Topics: Antigens, Bacterial; Lymphocyte Activation; Models, Molecular; Phosphoproteins; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes	2002
3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates. Journal of medicinal chemistry, 2003, Nov-20, Volume: 46, Issue:24 Topics: Animals; Crystallography, X-Ray; Dimethylallyltranstransferase; Diphosphonates; Imidazoles; Leishmania major; Models, Molecular; Picolinic Acids; Pyridines; Quantitative Structure-Activity Relationship; Zoledronic Acid	2003
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo. Journal of medicinal chemistry, 2004, Jan-01, Volume: 47, Issue:1 Topics: Animals; Antimalarials; Antiprotozoal Agents; Cell Line; Cricetinae; Diphosphonates; Entamoeba histolytica; Entamoebiasis; Humans; In Vitro Techniques; Liver Abscess; Malaria; Mice; Mice, Inbred BALB C; Plasmodium berghei; Plasmodium falciparum; Structure-Activity Relationship	2004
Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates. Journal of medicinal chemistry, 2004, Jan-15, Volume: 47, Issue:2 Topics: Alkyl and Aryl Transferases; Animals; Cell Division; Cell Line; Diphosphonates; Geranyltranstransferase; Humans; Leishmania major; Lymphocyte Activation; Models, Molecular; Quantitative Structure-Activity Relationship; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Tumor Necrosis Factor-alpha	2004
The purine transferase from Trypanosoma cruzi as a potential target for bisphosphonate-based chemotherapeutic compounds. Bioorganic & medicinal chemistry letters, 2004, Sep-06, Volume: 14, Issue:17 Topics: Animals; Diphosphonates; Drug Delivery Systems; Pentosyltransferases; Trypanosoma cruzi	2004
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption. Journal of medicinal chemistry, 2005, Apr-21, Volume: 48, Issue:8 Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Bone Resorption; Calcium; Dictyostelium; Diphosphonates; Geranyltranstransferase; Humans; In Vitro Techniques; Leishmania major; Metatarsal Bones; Mice; Models, Molecular; Pyridinium Compounds; Quantitative Structure-Activity Relationship; Receptors, Antigen, T-Cell, gamma-delta; Trypanocidal Agents	2005
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations. Journal of medicinal chemistry, 2005, May-05, Volume: 48, Issue:9 Topics: Aldose-Ketose Isomerases; Alkyl and Aryl Transferases; Animals; Antiprotozoal Agents; Cell Line; Diphosphonates; Fosfomycin; Geranyltranstransferase; Humans; Mice; Models, Molecular; Multienzyme Complexes; Oxidoreductases; Quantitative Structure-Activity Relationship; Toxoplasma; Toxoplasmosis	2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. Journal of medicinal chemistry, 2008, Apr-10, Volume: 51, Issue:7 Topics: Binding Sites; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Models, Molecular; Molecular Structure; Nitrogen; Stereoisomerism; Structure-Activity Relationship; Time Factors	2008
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. Journal of medicinal chemistry, 2008, Sep-25, Volume: 51, Issue:18 Topics: Antineoplastic Agents; Crystallography, X-Ray; Diphosphonates; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Farnesyltranstransferase; Humans; K562 Cells; Magnetic Resonance Spectroscopy; Models, Molecular; Quantitative Structure-Activity Relationship	2008
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6 Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics	2010
Remarkable potential of the α-aminophosphonate/phosphinate structural motif in medicinal chemistry. Journal of medicinal chemistry, 2011, Sep-08, Volume: 54, Issue:17 Topics: Amino Acid Motifs; Chemistry, Pharmaceutical; Humans; Organophosphonates; Phosphinic Acids	2011
Structural requirements for bisphosphonate binding on hydroxyapatite: NMR study of bisphosphonate partial esters. ACS medicinal chemistry letters, 2015, Apr-09, Volume: 6, Issue:4 Topics:	2015
Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility. Bioorganic & medicinal chemistry letters, 2020, 12-01, Volume: 30, Issue:23 Topics: Acetamides; Animals; Antimitotic Agents; Cell Line, Tumor; Diphosphonates; Drug Screening Assays, Antitumor; Embryo, Nonmammalian; Humans; Indoles; Sea Urchins; Solubility	2020
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1991, Volume: 6, Issue:9 Topics: Alendronate; Animals; Benzoates; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Ibandronic Acid; Injections, Intravenous; Osteoclasts; Pamidronate; Rats; Retinoids; Risedronic Acid; Spectrophotometry, Atomic; Tetracycline; Thyroxine	1991
Inhibition by a new bisphosphonate (AHBuBP) of bone resorption induced by the MBT-2 tumor of mice. Cancer, 1991, Feb-01, Volume: 67, Issue:3 Topics: Alendronate; Animals; Diphosphonates; Etidronic Acid; Female; Mice; Mice, Inbred C3H; Necrosis; Neoplasm Transplantation; Osteolysis; Pamidronate; Radiography; Skull; Urinary Bladder Neoplasms	1991
Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1990, Volume: 5, Issue:1 Topics: Alendronate; Animals; Bone Resorption; Cattle; Cell Survival; Diphosphonates; Etidronic Acid; In Vitro Techniques; Microscopy, Fluorescence; Microscopy, Phase-Contrast; Microscopy, Polarization; Osteoclasts; Pamidronate; Rats; Rats, Inbred Strains; Video Recording	1990
Effects of a new bisphosphonate (AHBuBP) on osteolysis induced by human prostate cancer cells in nude mice. The Journal of urology, 1990, Volume: 144, Issue:3 Topics: Adenocarcinoma; Alendronate; Animals; Diphosphonates; Etidronic Acid; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Osteolysis; Pamidronate; Prostatic Neoplasms	1990
Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone, 1995, Volume: 16, Issue:2 Topics: Alendronate; Animals; Autoradiography; Bone and Bones; Bone Resorption; Calcium; Carbon Radioisotopes; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Etidronic Acid; Hydroxycholecalciferols; Hypercalcemia; Male; Organ Culture Techniques; Osteoclasts; Pamidronate; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley; Tibia; Tissue Distribution	1995
Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1994, Volume: 9, Issue:4 Topics: Alendronate; Calcitriol; Calcium; Creatinine; Diphosphonates; Female; Humans; Hypercalcemia; Male; Neoplasms; Pamidronate; Parathyroid Hormone; Parathyroid Hormone-Related Protein; Phosphorus; Proteins	1994
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. The Journal of clinical investigation, 1993, Volume: 91, Issue:5 Topics: Alendronate; Animals; Animals, Newborn; Bone Resorption; Cell Line; Cells, Cultured; Clodronic Acid; Culture Media, Conditioned; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Ibandronic Acid; Kinetics; Osteoblasts; Pamidronate; Parathyroid Hormone; Rats; Rats, Wistar; Time Factors	1993
Different effects of three bisphosphonates on nitric oxide production by RAW 264 macrophage-like cells in vitro. The Journal of pharmacology and experimental therapeutics, 1996, Volume: 277, Issue:2 Topics: Alendronate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Clodronic Acid; Diphosphonates; Female; Lipopolysaccharides; Macrophages; Mice; Mice, Inbred BALB C; Nitric Oxide; Pamidronate	1996
Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1996, Volume: 11, Issue:10 Topics: Alendronate; Animals; Apoptosis; Bone Marrow; Bone Marrow Cells; Bone Resorption; Cell Division; Cell Nucleus; Cells, Cultured; Diphosphonates; DNA; DNA Fragmentation; Electrophoresis, Polyacrylamide Gel; Ibandronic Acid; Macrophages; Mice; Necrosis; Nitric Oxide; Pamidronate; Protein Biosynthesis	1996
Effects of bisphosphonates on alkaline phosphatase activity, mineralization, and prostaglandin E2 synthesis in the clonal osteoblast-like cell line MC3T3-E1. Prostaglandins, leukotrienes, and essential fatty acids, 1997, Volume: 56, Issue:2 Topics: Alendronate; Alkaline Phosphatase; Animals; Calcification, Physiologic; Calcium; Cell Line; Clodronic Acid; Culture Media; Dinoprostone; Diphosphonates; DNA; Glycerophosphates; Mice; Osteoblasts; Pamidronate	1997
Nonclinical model for assessing gastric effects of bisphosphonates. Digestive diseases and sciences, 1997, Volume: 42, Issue:2 Topics: Alendronate; Animals; Chelating Agents; Diphosphonates; Edetic Acid; Egtazic Acid; Etidronic Acid; Indomethacin; Male; Pamidronate; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stomach	1997
Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1997, Volume: 12, Issue:7 Topics: Adult; Alendronate; Amino Acid Sequence; Antibodies; Biomarkers; Bone Resorption; Collagen; Collagen Type I; Cross Reactions; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hyperparathyroidism; Menopause; Menstruation; Middle Aged; Molecular Sequence Data; Osteitis Deformans; Osteoporosis; Pamidronate; Peptides; Sensitivity and Specificity	1997
Rapid skeletal turnover and hypercalcemia associated with markedly elevated interleukin-6 levels in a young black man. Bone, 1998, Volume: 22, Issue:3 Topics: Adult; Alendronate; Alkaline Phosphatase; Black People; Bone and Bones; Bone Remodeling; Collagen; Collagen Type I; Diphosphonates; Humans; Hypercalcemia; Interleukin-6; Male; Osteoclasts; Osteolysis; Pamidronate; Peptides; Phosphates; Radionuclide Imaging	1998
Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders. Pharmaceutical research, 1998, Volume: 15, Issue:4 Topics: Alendronate; Animals; Anti-Inflammatory Agents; Betaine; Bone and Bones; Bone Resorption; Calcinosis; Chelating Agents; Diphosphonates; Edetic Acid; Hindlimb; Hydroxyapatites; Male; Pamidronate; Protein Synthesis Inhibitors; Rats; Structure-Activity Relationship; Tetracycline	1998
Effects of continuous alendronate treatment on bone mass and mechanical properties in ovariectomized rats: comparison with pamidronate and etidronate in growing rats. The Journal of pharmacology and experimental therapeutics, 1998, Volume: 286, Issue:1 Topics: Alendronate; Animals; Biomechanical Phenomena; Body Weight; Bone and Bones; Bone Density; Diphosphonates; Etidronic Acid; Female; Ovariectomy; Pamidronate; Rats; Rats, Sprague-Dawley	1998
The effect of alendronate on cytokine production, adhesion molecule expression, and transendothelial migration of human peripheral blood mononuclear cells. Calcified tissue international, 1998, Volume: 63, Issue:4 Topics: Alendronate; Antigens, CD; Cell Adhesion Molecules; Cell Communication; Cell Movement; Cytokines; Diphosphonates; Endothelium; Flow Cytometry; Humans; Integrin alpha4; Integrin alpha4beta1; Integrin beta1; Integrins; Intercellular Adhesion Molecule-1; Interferon-gamma; Interleukin-1; Leukocytes, Mononuclear; Pamidronate; Phenotype; Receptors, Lymphocyte Homing; Tumor Necrosis Factor-alpha	1998
Skin reactions associated with bisphosphonates: a report of 3 cases and an approach to management. The Journal of allergy and clinical immunology, 1998, Volume: 102, Issue:4 Pt 1 Topics: Adult; Alendronate; Antineoplastic Agents; Breast Neoplasms; Clodronic Acid; Diphosphonates; Drug Hypersensitivity; Etidronic Acid; Female; Humans; Middle Aged; Pamidronate; Skin Tests; Urticaria	1998
The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1999, Volume: 14, Issue:5 Topics: Alendronate; Apoptosis; Caco-2 Cells; Calcium; Cell Survival; Diphosphonates; Epithelial Cells; Humans; Intestinal Mucosa; Models, Biological; Nitrogen; Pamidronate; Solubility; Structure-Activity Relationship	1999
MMP inhibition and downregulation by bisphosphonates. Annals of the New York Academy of Sciences, 1999, Jun-30, Volume: 878 Topics: Alendronate; Antineoplastic Agents; Body Fluids; Collagenases; Diphosphonates; Gene Expression Regulation, Enzymologic; Humans; Metalloendopeptidases; Neoplasm Invasiveness; Pamidronate; Protease Inhibitors; Tumor Cells, Cultured	1999
Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate. Pharmaceutical research, 1999, Volume: 16, Issue:9 Topics: Administration, Oral; Alendronate; Animals; Antineoplastic Agents; Betaine; Bone Diseases; Bone Neoplasms; Calcium; Capsules; Carcinoma 256, Walker; Cell Line; Diphosphonates; Diuretics, Osmotic; Durapatite; Injections, Intravenous; Intestinal Absorption; Macrophages; Male; Mannitol; Osteogenesis; Pamidronate; Rats; Rats, Inbred Strains; Tight Junctions; Tissue Distribution	1999
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. The Journal of clinical investigation, 1999, Volume: 104, Issue:10 Topics: Alendronate; Animals; Apoptosis; Calcitonin; Cell Line; Cells, Cultured; Dexamethasone; Diphosphonates; Etidronic Acid; Etoposide; In Situ Nick-End Labeling; Mice; Osteoblasts; Osteocytes; Pamidronate; Prednisolone; Skull; Tumor Necrosis Factor-alpha	1999
N-bisphosphonates cause gastric epithelial injury independent of effects on the microcirculation. Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:12 Topics: Administration, Topical; Alendronate; Animals; Dinoprostone; Diphosphonates; Drug Interactions; Epithelium; Male; Microcirculation; Neutrophil Infiltration; Nitric Oxide; Nitric Oxide Donors; Pamidronate; Rats; Rats, Wistar; Stomach; Time Factors	1999
Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Archives of biochemistry and biophysics, 2000, Jan-01, Volume: 373, Issue:1 Topics: Alendronate; Alkyl and Aryl Transferases; Animals; Carbon-Carbon Double Bond Isomerases; Diphosphonates; Enzyme Inhibitors; Farnesyltranstransferase; Geranyltranstransferase; Hemiterpenes; Humans; In Vitro Techniques; Kinetics; Lipids; Liver; Male; Mevalonic Acid; Osteoclasts; Pamidronate; Protein Prenylation; Rats; Rats, Sprague-Dawley; Recombinant Proteins	2000
A 73-year-old woman with osteoporosis, 1 year later. JAMA, 2000, Jan-26, Volume: 283, Issue:4 Topics: Aged; Alendronate; Diphosphonates; Female; Humans; Osteoporosis; Pamidronate	2000
Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood, 2000, Jul-15, Volume: 96, Issue:2 Topics: Alendronate; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Bone Marrow Cells; Cell Division; Cell Survival; Cytotoxicity, Immunologic; Diphosphonates; Humans; Ibandronic Acid; Interferon-gamma; Interleukin-2; Kinetics; Lectins, C-Type; Lymphocyte Activation; Multiple Myeloma; Pamidronate; Plasma Cells; Receptors, Interleukin-2; T-Lymphocytes; Tumor Cells, Cultured	2000
Gastric damage in the rat with nitrogen-containing bisphosphonates depends on pH. Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:9 Topics: Administration, Oral; Alendronate; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Hydrogen-Ion Concentration; Indomethacin; Male; Pamidronate; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stomach; Structure-Activity Relationship	2000
Case of an ivory vertebra. Journal of endocrinological investigation, 2000, Volume: 23, Issue:8 Topics: Alendronate; Alkaline Phosphatase; Biopsy; Bone Marrow; Carcinoid Tumor; Diagnosis, Differential; Diphosphonates; Humans; Liver Neoplasms; Lumbar Vertebrae; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Osteitis Deformans; Osteoblasts; Pamidronate; Spinal Neoplasms; Technetium; Tomography, X-Ray Computed	2000
Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Digestive diseases and sciences, 2000, Volume: 45, Issue:9 Topics: Alendronate; Animals; Anti-Inflammatory Agents; Diphosphonates; Etidronic Acid; Gastric Mucosa; Indomethacin; Male; Pamidronate; Phosphatidylcholines; Rats; Rats, Sprague-Dawley; Risedronic Acid; Surface Properties	2000
Bisphosphonate therapy in fibrous dysplasia. Clinical orthopaedics and related research, 2001, Issue:382 Topics: Administration, Oral; Adult; Aged; Alendronate; Biomarkers; Bone and Bones; Collagen; Collagen Type I; Diphosphonates; Female; Fibrous Dysplasia of Bone; Follow-Up Studies; Fractures, Spontaneous; Humans; Injections, Intravenous; Male; Middle Aged; Osteogenesis; Osteolysis; Pain Measurement; Pamidronate; Peptides; Radiography; Statistics, Nonparametric	2001
Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood, 2001, Sep-01, Volume: 98, Issue:5 Topics: Alendronate; Antigens; Cell Line, Transformed; Cytotoxicity, Immunologic; Diphosphonates; Etidronic Acid; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Humans; Interferon-gamma; Interleukin-2; Jurkat Cells; Lymphocyte Activation; Monocytes; Multiple Myeloma; Neoplasms; Neoplastic Stem Cells; Osteoclasts; Osteoporosis; Pamidronate; Receptors, Antigen, T-Cell, gamma-delta; Recombinant Fusion Proteins; Risedronic Acid; Structure-Activity Relationship; T-Lymphocyte Subsets; Transfection	2001
Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2001, Volume: 16, Issue:9 Topics: Alendronate; Calcitriol; Calcium; Cervical Vertebrae; Diphosphonates; Female; Humans; Hypocalcemia; Hypoparathyroidism; Middle Aged; Osteitis Deformans; Pamidronate; Pelvis; Scapula; Tibia; Time Factors; Treatment Outcome	2001
Do different aminobisphosphonates have similar preventive effect on experimental thyroid hormone-induced osteopenia in rats? Calcified tissue international, 2001, Volume: 69, Issue:5 Topics: Alendronate; Animals; Body Weight; Bone Diseases, Metabolic; Diphosphonates; Female; Pamidronate; Rats; Rats, Sprague-Dawley; Thyroxine	2001
Synthesis, characterization and biodistribution of bisphosphonates Sm-153 complexes: correlation with molecular modeling interaction studies. Nuclear medicine and biology, 2002, Volume: 29, Issue:3 Topics: Alendronate; Animals; Bone and Bones; Diphosphonates; Durapatite; Energy Transfer; Female; Mice; Models, Molecular; Molecular Conformation; Pamidronate; Radiochemistry; Radioisotopes; Radiopharmaceuticals; Samarium; Tissue Distribution	2002
Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Experimental & molecular medicine, 2002, May-31, Volume: 34, Issue:2 Topics: Alendronate; Animals; Bone Resorption; Carrier Proteins; Cells, Cultured; Diphosphonates; Gene Expression Regulation; Glycoproteins; Membrane Glycoproteins; Mice; Mice, Inbred ICR; Osteoblasts; Osteoclasts; Osteoprotegerin; Pamidronate; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction	2002
Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis. The Netherlands journal of medicine, 2002, Volume: 60, Issue:8 Topics: Administration, Oral; Aged; Alendronate; Bone Density; Diphosphonates; Female; Fractures, Spontaneous; Humans; Injections, Intravenous; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Radiography; Retrospective Studies; Spinal Fractures; Time Factors	2002
A quantitative structure-activity relationship and pharmacophore modeling investigation of aryl-X and heterocyclic bisphosphonates as bone resorption agents. Journal of medicinal chemistry, 2003, Jul-03, Volume: 46, Issue:14 Topics: Alendronate; Bone Resorption; Diphosphonates; Heterocyclic Compounds; Models, Molecular; Pamidronate; Quantitative Structure-Activity Relationship	2003
Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcified tissue international, 2004, Volume: 75, Issue:1 Topics: Alendronate; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Diphosphonates; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; Flow Cytometry; Giant Cell Tumor of Bone; Humans; Imidazoles; In Situ Nick-End Labeling; Osteoclasts; Pamidronate; Stromal Cells; Tumor Cells, Cultured; Zoledronic Acid	2004
By the way, doctor. My wife is 80. In order to increase her bone calcium, she takes calcium citrate tablets. Her doctor now wants to put her on Aredia by IV injection every three months. Since this is not FDA approved, is it a good idea? Harvard health letter, 2004, Volume: 29, Issue:8 Topics: Aged; Aged, 80 and over; Alendronate; Antineoplastic Agents; Calcium Citrate; Diphosphonates; Female; Humans; Osteoporosis; Pamidronate	2004
In vitro toxicity of bisphosphonates on human neuroblastoma cell lines. Anti-cancer drugs, 2004, Volume: 15, Issue:8 Topics: Alendronate; Apoptosis; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Diphosphonates; Drug Screening Assays, Antitumor; Germany; Humans; Ibandronic Acid; Imidazoles; Neuroblastoma; Pamidronate; Time Factors; Zoledronic Acid	2004
Bisphosphonates and avascular necrosis of the jaw: a possible association. The Medical journal of Australia, 2005, Apr-18, Volume: 182, Issue:8 Topics: Aged; Aged, 80 and over; Alendronate; Anti-Inflammatory Agents; Diphosphonates; Female; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Long-Term Care; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteitis Deformans; Osteonecrosis; Pamidronate; Risk Factors; Tomography, X-Ray Computed	2005
The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2005, Volume: 16, Issue:11 Topics: Absorptiometry, Photon; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Anti-Inflammatory Agents; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Hip; Humans; Injections, Intravenous; Male; Middle Aged; Osteoporosis; Pamidronate; Prospective Studies; Spine	2005
Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations. Biological trace element research, 2005, Volume: 104, Issue:2 Topics: Alendronate; Alkaline Phosphatase; Animals; Bone and Bones; Bone Resorption; Cations, Divalent; Diphosphonates; Imidazoles; Isoenzymes; Magnesium; Osteoblasts; Osteosarcoma; Pamidronate; Rats; Tumor Cells, Cultured; Zinc; Zoledronic Acid	2005
Bisphosphonates decrease telomerase activity and hTERT expression in MCF-7 breast cancer cells. Molecular and cellular endocrinology, 2005, Aug-30, Volume: 240, Issue:1-2 Topics: Alendronate; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Clodronic Acid; Diphosphonates; DNA-Binding Proteins; Female; Gene Expression; Humans; Pamidronate; Telomerase; Tumor Cells, Cultured	2005
Osteonecrosis of the jaw and bisphosphonates. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Alendronate; Animals; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Osteoporosis; Pamidronate; Zoledronic Acid	2005
High-performance liquid chromatography method for determining alendronate sodium in human plasma by detecting fluorescence: application to a pharmacokinetic study in humans. Journal of pharmaceutical and biomedical analysis, 2006, Jan-23, Volume: 40, Issue:1 Topics: Alendronate; Bone Density Conservation Agents; Calibration; Chemistry Techniques, Analytical; Chemistry, Pharmaceutical; Chromatography; Chromatography, High Pressure Liquid; Chromatography, Liquid; Citrates; Diphosphonates; Fluorenes; Humans; Hydrogen-Ion Concentration; Kinetics; Models, Chemical; Pamidronate; Quality Control; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Time Factors; Trichloroacetic Acid	2006
Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports. Journal of endodontics, 2005, Volume: 31, Issue:10 Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Osteonecrosis; Pamidronate; Zoledronic Acid	2005
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2005, Volume: 63, Issue:11 Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Dental Caries; Dexamethasone; Diphosphonates; Drug Interactions; Female; Humans; Hyperostosis; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Osteopetrosis; Osteoporosis; Pamidronate; Periodontitis; Prostatic Neoplasms; Risk Factors; Tooth Extraction; Zoledronic Acid	2005
[Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates]. Mund-, Kiefer- und Gesichtschirurgie : MKG, 2005, Volume: 9, Issue:4 Topics: Aged; Alendronate; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Mouth Diseases; Osteonecrosis; Osteoporosis, Postmenopausal; Pamidronate; Plasmacytoma; Radiography, Panoramic; Risk Factors; Zoledronic Acid	2005
By the way, doctor. I've heard that taking Fosamax for a long time causes the jawbone to deteriorate. Do you know anything about this? Harvard women's health watch, 2005, Volume: 13, Issue:4 Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Osteoclasts; Osteonecrosis; Pamidronate; Zoledronic Acid	2005
Relationship between periodontal disease and systemic diseases. Texas dental journal, 2006, Volume: 123, Issue:2 Topics: Alendronate; Bone Density Conservation Agents; Contraindications; Dental Implantation, Endosseous; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Osteonecrosis; Pamidronate; Zoledronic Acid	2006
Differential effects of bisphosphonates on breast cancer cell lines. Cancer letters, 2007, Feb-08, Volume: 246, Issue:1-2 Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Cyclin D1; Diphosphonates; DNA Fragmentation; Etidronic Acid; Female; Flow Cytometry; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Risedronic Acid; RNA, Messenger; Zoledronic Acid	2007
Evaluation of multidimensional capillary electrophoretic methodologies for determination of amino bisphosphonate pharmaceuticals. Journal of chromatography. A, 2006, Oct-13, Volume: 1130, Issue:1 Topics: Alendronate; Diphosphonates; Electrophoresis, Capillary; Humans; Pamidronate; Reproducibility of Results	2006
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. Acta haematologica, 2007, Volume: 117, Issue:3 Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Mandible; Maxilla; Middle Aged; Multiple Myeloma; Necrosis; Osteonecrosis; Pamidronate; Tomography, X-Ray Computed; Zoledronic Acid	2007
Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta bio-medica : Atenei Parmensis, 2006, Volume: 77, Issue:2 Topics: Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antifungal Agents; Bone Density Conservation Agents; Bone Neoplasms; Chlorhexidine; Curettage; Diphosphonates; Female; Humans; Hydrogen Peroxide; Imidazoles; Jaw Diseases; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Mouthwashes; Multiple Myeloma; Osteonecrosis; Osteoporosis; Pamidronate; Radiography; Time Factors; Zoledronic Acid	2006
Amino-bisphosphonates decrease hTERT gene expression in breast cancer in vitro. Aging clinical and experimental research, 2007, Volume: 19, Issue:2 Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Clodronic Acid; Diphosphonates; Female; Gene Expression Regulation, Neoplastic; Humans; Pamidronate; Telomerase	2007
[Advances in the research of bisphosphonate-associated osteonecrosis of the jaws]. Shanghai kou qiang yi xue = Shanghai journal of stomatology, 2006, Volume: 15, Issue:6 Topics: Alendronate; Biomedical Research; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Humans; Osteonecrosis; Pamidronate	2006
Development and application of a high-performance liquid chromatography-mass spectrometry method to determine alendronate in human urine. Journal of chromatography. A, 2007, Aug-10, Volume: 1160, Issue:1-2 Topics: Alendronate; Biological Availability; Chromatography, High Pressure Liquid; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Mass Spectrometry; Pamidronate; Reference Standards	2007
NMR investigations of the static and dynamic structures of bisphosphonates on human bone: a molecular model. Journal of the American Chemical Society, 2008, Jan-30, Volume: 130, Issue:4 Topics: Alendronate; Biochemistry; Bone and Bones; Bone Density Conservation Agents; Crystallography, X-Ray; Diphosphonates; Etidronic Acid; Humans; Hydrogen; Imidazoles; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Pamidronate; Protein Structure, Tertiary; Risedronic Acid; Zoledronic Acid	2008
Metaphyseal sclerosis associated with bisphosphonate therapy. Journal of pediatric endocrinology & metabolism : JPEM, 2007, Volume: 20, Issue:11 Topics: Alendronate; Bone and Bones; Bone Density Conservation Agents; Dermatomyositis; Diphosphonates; Humans; Osteogenesis Imperfecta; Pamidronate; Radiography; Sclerosis	2007
Comment on: Bisphosphonates and osteonecrosis of the jaw. Rheumatology (Oxford, England), 2008, Volume: 47, Issue:3 Topics: Administration, Oral; Adolescent; Adult; Alendronate; Child; Child, Preschool; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Jaw Diseases; Male; Osteonecrosis; Pamidronate; Prospective Studies; Risk Assessment	2008
Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcified tissue international, 2008, Volume: 82, Issue:3 Topics: Alendronate; Animals; Animals, Newborn; Apoptosis; Bone Density Conservation Agents; Calcification, Physiologic; Cell Survival; Cells, Cultured; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Mice; Osteoblasts; Osteocalcin; Osteoclasts; Osteogenesis; Pamidronate; Protein Prenylation; Rabbits; Skull	2008
Effects of alendronate and pamidronate on cultured rat metatarsal bones: failure to prevent dexamethasone-induced growth retardation. Bone, 2008, Volume: 42, Issue:4 Topics: Alendronate; Animals; Bone Density; Cell Differentiation; Cell Line; Cell Proliferation; Chondrocytes; Cytoprotection; Dexamethasone; Diphosphonates; Foot Bones; Humans; Pamidronate; Rats; Rats, Sprague-Dawley; Tissue Culture Techniques	2008
Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina (Philadelphia, Pa.), 2008, Volume: 28, Issue:6 Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Databases, Factual; Diphosphonates; Drug Prescriptions; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Pamidronate; Pharmacy Service, Hospital; Product Surveillance, Postmarketing; Scleritis; United States; United States Department of Veterans Affairs; Uveitis; Veterans	2008
Enhanced bone morphogenetic protein-2 performance on hydroxyapatite ceramic surfaces. Journal of biomedical materials research. Part A, 2009, Sep-15, Volume: 90, Issue:4 Topics: Alendronate; Animals; Bone Morphogenetic Protein 2; Cell Differentiation; Cell Line; Ceramics; Coated Materials, Biocompatible; Diphosphonates; Durapatite; Immobilized Proteins; Mice; Muramidase; Osteoblasts; Pamidronate	2009
Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells. European journal of pharmacology, 2008, Dec-14, Volume: 600, Issue:1-3 Topics: 3T3 Cells; Alendronate; Animals; Bone Density Conservation Agents; Calcium; Calcium Channels, L-Type; Cattle; Cell Line; Diabetes Complications; Diphosphonates; Dose-Response Relationship, Drug; Glycation End Products, Advanced; Imidazoles; Mice; Osteoblasts; Osteoporosis; Pamidronate; Rats; Reactive Oxygen Species; Serum Albumin, Bovine; Time Factors; Zoledronic Acid	2008
Alendronate and Pamidronate calcium phosphate bone cements: setting properties and in vitro response of osteoblast and osteoclast cells. Journal of inorganic biochemistry, 2009, Volume: 103, Issue:1 Topics: Alendronate; Bone Cements; Bone Density Conservation Agents; Calcium Phosphates; Cell Differentiation; Cell Line; Cell Proliferation; Diphosphonates; Humans; Microscopy, Electron, Scanning; Osteoblasts; Osteoclasts; Pamidronate	2009
Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina (Philadelphia, Pa.), 2009, Volume: 29, Issue:2 Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Databases, Factual; Diphosphonates; Drug Prescriptions; Humans; Infusions, Parenteral; Pamidronate; Pharmacy Service, Hospital; Product Surveillance, Postmarketing; Scleritis; United States; United States Department of Veterans Affairs; Uveitis; Veterans	2009
Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2009, Volume: 67, Issue:4 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Angiogenesis Inhibitors; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bone Density Conservation Agents; Diabetes Mellitus, Type 2; Diphosphonates; Female; Follow-Up Studies; Glucocorticoids; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Minimally Invasive Surgical Procedures; Oral Surgical Procedures; Osteonecrosis; Pamidronate; Risk Factors; Smoking; Time Factors; Treatment Outcome; Wound Healing; Zoledronic Acid	2009
Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2009, Volume: 67, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Pamidronate; Treatment Outcome; Zoledronic Acid	2009
Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2009, Volume: 67, Issue:7 Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Early Diagnosis; Female; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Pamidronate; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Technetium Compounds; Zoledronic Acid	2009
Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clinical oral investigations, 2010, Volume: 14, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Connective Tissue; Diphosphonates; Female; Humans; Imidazoles; Inflammation; Jaw; Jaw Diseases; Male; Mandibular Diseases; Maxillary Diseases; Microscopy, Electron, Scanning; Middle Aged; Osteomyelitis; Osteonecrosis; Osteoporosis; Osteoradionecrosis; Pamidronate; Time Factors; Zoledronic Acid	2010
In vitro determination of the release of alendronic acid from alendronate tablets of different brands during deglutition. Journal of pharmaceutical sciences, 2009, Volume: 98, Issue:10 Topics: Alendronate; Algorithms; Bone Density Conservation Agents; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Deglutition; Diphosphonates; Drugs, Generic; Indicators and Reagents; Kinetics; Pamidronate; Solubility; Solvents; Tablets; Therapeutic Equivalency	2009
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2010, Volume: 68, Issue:5 Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, External; Etidronic Acid; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Inflammation Mediators; Injections, Intraperitoneal; Injections, Subcutaneous; Interleukin-1; Male; Mice; Mice, Inbred BALB C; Necrosis; Osteonecrosis; Osteosclerosis; Pamidronate; Pravastatin; Radionuclide Imaging; Radiopharmaceuticals; Risedronic Acid; Technetium; Tibia; Time Factors; Zoledronic Acid	2010
An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem, 2010, May-03, Volume: 5, Issue:5 Topics: Alendronate; Anabolic Agents; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Drug Delivery Systems; Durapatite; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Nuclear Magnetic Resonance, Biomolecular; Pamidronate; Risedronic Acid; Zoledronic Acid	2010
Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2010, Volume: 109, Issue:5 Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Diphosphonates; Dry Socket; Female; Humans; Imaging, Three-Dimensional; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Oroantral Fistula; Osteonecrosis; Osteosclerosis; Pamidronate; Radiography, Dental, Digital; Radiography, Panoramic; Tooth Socket; Zoledronic Acid	2010
Possible beneficial effect of bisphosphonates in osteonecrosis of the knee. Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 2010, Volume: 18, Issue:12 Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Bone Density Conservation Agents; Bone Marrow Diseases; Collagen Type I; Diphosphonates; Edema; Humans; Knee; Leg Bones; Magnetic Resonance Imaging; Middle Aged; Osteocalcin; Osteonecrosis; Pain Measurement; Pamidronate; Peptide Fragments; Peptides; Procollagen; Prospective Studies	2010
Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2010, Volume: 110, Issue:1 Topics: Aged; Alcohol Drinking; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Chronic Disease; Clindamycin; Cohort Studies; Combined Modality Therapy; Debridement; Diphosphonates; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Jaw Diseases; Male; Oral Fistula; Osteonecrosis; Pamidronate; Penicillins; Prospective Studies; Remission Induction; Risk Factors; Smoking; Tooth Extraction; Treatment Outcome; Wound Healing; Zoledronic Acid	2010
Bisphosphonate protonation states, conformations, and dynamics on bone mineral probed by solid-state NMR without isotope enrichment. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2010, Volume: 76, Issue:1 Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Crystallization; Diphosphonates; Horses; Imidazoles; Magnetic Resonance Spectroscopy; Molecular Structure; Pamidronate; Structure-Activity Relationship; Technology, Pharmaceutical; Zoledronic Acid	2010
Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6. Journal of periodontal research, 2011, Volume: 46, Issue:1 Topics: Alendronate; Analysis of Variance; Bone Density Conservation Agents; Bone Remodeling; Cells, Cultured; Diphosphonates; Fibroblasts; Gingiva; Humans; Interleukin-1beta; Interleukin-6; Lipopolysaccharides; Necrosis; Osteoclasts; Osteoprotegerin; Pamidronate; RANK Ligand; Statistics, Nonparametric	2011
Acute effects of intravenous administration of pamidronate in patients with osteoporosis. Journal of Korean medical science, 2010, Volume: 25, Issue:9 Topics: Acute-Phase Proteins; Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Blood Cells; Bone Density Conservation Agents; C-Reactive Protein; Calcium; Collagen Type I; Diphosphonates; Female; Humans; Injections, Intravenous; Interferon-gamma; Interleukin-6; Male; Middle Aged; Osteoporosis; Pamidronate; Peptides; RNA, Messenger; Tumor Necrosis Factor-alpha	2010
Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis. Bone, 2011, Volume: 48, Issue:2 Topics: Alendronate; Animals; Apoptosis; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cells, Cultured; Diphosphonates; Female; Humans; Immunoblotting; Mice; Microspectrophotometry; Osteoclasts; Pamidronate; Polymerase Chain Reaction	2011
Use of bisphosphonates to treat severe idiopathic hypercalcaemia in a young Ragdoll cat. Journal of feline medicine and surgery, 2011, Volume: 13, Issue:2 Topics: Alendronate; Animals; Bone Density Conservation Agents; Cat Diseases; Cats; Diphosphonates; Female; Follow-Up Studies; Hypercalcemia; Pamidronate; Severity of Illness Index; Treatment Outcome	2011
99mTc(CO)3-labeled pamidronate and alendronate for bone imaging. Dalton transactions (Cambridge, England : 2003), 2011, Mar-28, Volume: 40, Issue:12 Topics: Alendronate; Animals; Bone and Bones; Crystallography, X-Ray; Diphosphonates; Female; Mice; Molecular Conformation; Pamidronate; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Technetium; Tissue Distribution; Tomography, Emission-Computed, Single-Photon	2011
[Prosthetic rehabilitation after osteonecrosis of the jaws due to histiocytosis X and treatment with bisphosphonates apropos of a case]. Odonto-stomatologie tropicale = Tropical dental journal, 2010, Volume: 33, Issue:132 Topics: Adult; Alendronate; Bone Density Conservation Agents; Denture Design; Denture, Partial, Fixed; Denture, Partial, Temporary; Diphosphonates; Female; Histiocytosis, Langerhans-Cell; Humans; Imidazoles; Jaw, Edentulous, Partially; Mandibular Diseases; Osteonecrosis; Pamidronate; Risk Factors; Tooth Extraction; Zoledronic Acid	2010
N⁴-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine-new drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate). Bioorganic & medicinal chemistry, 2011, Jun-01, Volume: 19, Issue:11 Topics: Alendronate; Animals; Antimetabolites, Antineoplastic; Arabinofuranosyluracil; Bone and Bones; Bone Density Conservation Agents; Cell Line, Tumor; Cytidine; Diphosphonates; Drug Screening Assays, Antitumor; Durapatite; Fluorouracil; Humans; Macrophages; Mice; Pamidronate; Uridine; Zidovudine	2011
Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts. Clinical oral investigations, 2012, Volume: 16, Issue:4 Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cell Culture Techniques; Cell Differentiation; Culture Media; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+); Humans; Macrophage Colony-Stimulating Factor; Male; Mesenchymal Stem Cells; Osteoblasts; Osteoclasts; Osteogenesis; Osteoprotegerin; Pamidronate; Real-Time Polymerase Chain Reaction; Time Factors; Young Adult	2012
[Inflammation of the jaws during treatment with bisphosphonates]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:41 Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Drug Approval; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Opportunistic Infections; Osteomyelitis; Osteonecrosis; Osteoporosis; Pamidronate; Practice Guidelines as Topic; Risk Factors; Zoledronic Acid	2011
The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2012, Volume: 40, Issue:8 Topics: Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Chromatography, High Pressure Liquid; Collagen Type I; Coloring Agents; Diphosphates; Diphosphonates; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Fibroblasts; Follow-Up Studies; Gingiva; Humans; Imidazoles; Osteoblasts; Osteocalcin; Osteosarcoma; Pamidronate; Tetrazolium Salts; Thiazoles; Zoledronic Acid	2012
Uncommon transient osteoporosis of pregnancy at multiple sites associated with cytomegalovirus infection: is there a link? The Israel Medical Association journal : IMAJ, 2011, Volume: 13, Issue:11 Topics: Absorptiometry, Photon; Adult; Alendronate; Ankle Joint; Bone Density Conservation Agents; Cytomegalovirus Infections; Diphosphonates; Female; Hip Joint; Humans; Knee Joint; Magnetic Resonance Imaging; Osteoporosis; Pamidronate; Pregnancy; Pregnancy Complications; Radionuclide Imaging	2011
Cutting edge: nitrogen bisphosphonate-induced inflammation is dependent upon mast cells and IL-1. Journal of immunology (Baltimore, Md. : 1950), 2012, Apr-01, Volume: 188, Issue:7 Topics: Alendronate; Animals; Chemotaxis; Clodronic Acid; Diphosphonates; Imidazoles; Interleukin-1alpha; Interleukin-1beta; Leukocytes; Mast Cells; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Mutant Strains; Myeloid Differentiation Factor 88; Neutrophils; Pamidronate; Peritonitis; Receptors, Interleukin-1; Zoledronic Acid	2012
Osteopathology induced by bisphosphonates and dental implants: clinical observations. Clinical oral investigations, 2013, Volume: 17, Issue:1 Topics: Actinomycosis; Administration, Intravenous; Administration, Oral; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Debridement; Dental Implants; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Male; Mandible; Mandibular Neoplasms; Maxilla; Neoplasms; Osteomyelitis; Osteoporosis; Pamidronate; Risk Factors; Time Factors; Zoledronic Acid	2013
[Simultaneous determination of alendronate, pamidronate, ibandronate and risedronate using ion chromatography with integrated pulsed amperometric detection]. Se pu = Chinese journal of chromatography, 2012, Volume: 30, Issue:4 Topics: Alendronate; Chromatography, Ion Exchange; Diphosphonates; Electrochemical Techniques; Etidronic Acid; Humans; Ibandronic Acid; Pamidronate; Risedronic Acid	2012
Healing of extraction sockets and augmented alveolar defects following 1-year treatment with bisphosphonate. The Journal of craniofacial surgery, 2013, Volume: 24, Issue:1 Topics: Alendronate; Alveolar Ridge Augmentation; Animals; Bone Transplantation; Collagen Type I; Cone-Beam Computed Tomography; Diphosphonates; Dogs; Female; Humans; Mandible; Pamidronate; Peptides; Random Allocation; Surgical Flaps; Tooth Extraction; Transplantation, Homologous; Wound Healing	2013
Effect of bisphosphonates on the rapidly growing male murine skeleton. Endocrinology, 2014, Volume: 155, Issue:4 Topics: Alendronate; Animals; Apoptosis; Biomechanical Phenomena; Bone and Bones; Bone Development; Bone Resorption; Chondrocytes; Clodronic Acid; Diphosphonates; Hypertrophy; Imidazoles; Male; Mice; Mice, Inbred C57BL; Pamidronate; Phenotype; X-Ray Microtomography; Zoledronic Acid	2014
A simple evaluation method for early detection of bisphosphonate-related osteonecrosis of the mandible using computed tomography. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2014, Volume: 42, Issue:6 Topics: Administration, Intravenous; Administration, Oral; Alendronate; Alveolar Process; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Early Diagnosis; Etidronic Acid; Female; Humans; Image Processing, Computer-Assisted; Imidazoles; Male; Mandible; Mandibular Diseases; Middle Aged; Osteolysis; Osteosclerosis; Pamidronate; Risedronic Acid; Risk Factors; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid	2014
[Effects of four bisphosphonates on macrophage phagocytosis: quantitative measurement by flow cytometry using high-fluorescence particles and human monocytic cell line THP-1]. Rinsho byori. The Japanese journal of clinical pathology, 2014, Volume: 62, Issue:1 Topics: Alendronate; Apoptosis; Bone Density Conservation Agents; Cell Line; Diphosphonates; Flow Cytometry; Fluorescent Dyes; Humans; Imidazoles; Macrophages; Pamidronate; Phagocytosis; Zoledronic Acid	2014
High doses of bisphosphonates reduce osteoblast-like cell proliferation by arresting the cell cycle and inducing apoptosis. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2015, Volume: 43, Issue:3 Topics: Alendronate; Apoptosis; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Coloring Agents; Diphosphonates; Dose-Response Relationship, Drug; Flow Cytometry; G1 Phase; Humans; Ibandronic Acid; Necrosis; Osteoblasts; Pamidronate; Resting Phase, Cell Cycle; Spectrophotometry; Tetrazolium Salts; Thiazoles; Time Factors	2015
Effects of alendronate and pamidronate on apoptosis and cell proliferation in cultured primary human gingival fibroblasts. Human & experimental toxicology, 2015, Volume: 34, Issue:11 Topics: Adolescent; Adult; Alendronate; Apoptosis; Bone Density Conservation Agents; Cell Proliferation; Cells, Cultured; Diphosphonates; Female; Fibroblasts; Gingiva; Humans; Male; Pamidronate; Young Adult	2015
Concentration-dependent effects of alendronate and pamidronate functionalized gold nanoparticles on osteoclast and osteoblast viability. Journal of biomedical materials research. Part B, Applied biomaterials, 2017, Volume: 105, Issue:1 Topics: Alendronate; Animals; Cell Survival; Diphosphonates; Dose-Response Relationship, Drug; Gold; Metal Nanoparticles; Mice; Osteoblasts; Osteoclasts; Pamidronate; RAW 264.7 Cells	2017
[Bisphosphonate use and related pharmaceutical issues II]. Acta pharmaceutica Hungarica, 2016, Volume: 86, Issue:1 Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Confounding Factors, Epidemiologic; Diphosphonates; Drug Costs; Drug Prescriptions; Drugs, Generic; Humans; Hungary; Ibandronic Acid; Imidazoles; National Health Programs; Osteoporosis; Pamidronate; Retrospective Studies; Risedronic Acid; Zoledronic Acid	2016
The Bisphosphonate Pamidronate is an Intestinal Antiinflammatory Agent in Rat and Mouse Experimental Colitis. Inflammatory bowel diseases, 2016, Volume: 22, Issue:11 Topics: Alendronate; Animals; Anti-Inflammatory Agents; Colitis; Dextran Sulfate; Diphosphonates; Ibandronic Acid; Immunologic Factors; Intestinal Mucosa; Mice; Pamidronate; Rats; T-Lymphocytes; Trinitrobenzenesulfonic Acid	2016
New insights into human farnesyl pyrophosphate synthase inhibition by second-generation bisphosphonate drugs. Journal of computer-aided molecular design, 2017, Volume: 31, Issue:7 Topics: Alendronate; Binding Sites; Bone Density Conservation Agents; Diphosphonates; Drug Discovery; Geranyltranstransferase; Hemiterpenes; Humans; Molecular Dynamics Simulation; Organophosphorus Compounds; Pamidronate; Protein Binding; Structure-Activity Relationship; Thermodynamics	2017
Clinical significance of increased serum levels of FGF-23 in fibrous dysplasia. Medicina clinica, 2018, 07-23, Volume: 151, Issue:2 Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density Conservation Agents; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibrous Dysplasia of Bone; Humans; Male; Middle Aged; Osteomalacia; Pamidronate; Phosphorus; Reference Values; Young Adult; Zoledronic Acid	2018
Immediate implant placement following 1-year treatment with oral versus intravenous bisphosphonates: a histomorphometric canine study on peri-implant bone. Clinical oral investigations, 2019, Volume: 23, Issue:4 Topics: Alendronate; Animals; Bone Density Conservation Agents; Dental Implantation, Endosseous; Dental Implants; Dogs; Female; Osseointegration; Pamidronate	2019
Tissue-Nonspecific Alkaline Phosphatase (TNAP) as the Enzyme Involved in the Degradation of Nucleotide Analogues in the Ligand Docking and Molecular Dynamics Approaches. Biomolecules, 2021, 07-27, Volume: 11, Issue:8 Topics: Adenosine Triphosphate; Alendronate; Alkaline Phosphatase; Computational Biology; Diphosphates; Diphosphonates; Enzymes; Humans; Hydrogen Bonding; Ligands; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Pamidronate; Phosphates; Protein Conformation; Thermodynamics; Zoledronic Acid	2021
Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system. Scientific reports, 2023, 07-05, Volume: 13, Issue:1 Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Femur; Humans; Ibandronic Acid; Osteoporosis; Pamidronate; Pharmaceutical Preparations; Risedronic Acid	2023